Quick search:
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update
2 MEI Pharma
3 MEI Pharma expands early-stage zandelisib trial in specific blood cancer cohorts
4 Analyst Rating: Will MEI Pharma Inc (MEIP) Stock Outperform the Market?
5 Do Analysts Agree on MEI Pharma Inc (MEIP) Stock's Target Price?
6 $2.08 Million in Sales Expected for MEI Pharma, Inc. (NASDAQ:MEIP) This Quarter
7 MEI Pharma (MEIP) Reports Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update
8 Why MEI Pharma Is Tanking 15.3% Today
9 MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights
10 MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program
11 MEI PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc.
12 MEI Pharma Reports Fiscal Third-Quarter 2020 Results and Recent Corporate Highlights
13 MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences
14 Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal Phase 2 Study of Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma
15 MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing
16 Histone Deacetylase 1 Market Global Competition, Size, Business Outlook Market Dynamics 2021 Forecast to 2027 4SC AG, Acetylon Pharmaceuticals, Inc.
17 MEI Pharma Announces Fast Track Designation Granted by US FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma
18 MEI Pharma: Give It Another Chance
19 Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes
20 MEI Pharma nabs $100M upfront and weighty biobucks in upgraded Kyowa Kirin cancer drug deal
21 Histone Deacetylase Inhibitors Market to witness astonishing growth with Key Players : 4SC AG, Acetylon Pharmaceuticals, Celleron Therapeutics, Chroma Therapeutics, CrystalGenomics
22 Global Myelodysplastic syndromes (MDS) Market With COVID 19 Impact Analysis| Leading Players In-depth Analysis Research Report Foresight to 2027 – KSU | The Sentinel Newspaper
23 Growth Investors: Industry Analysts Just Upgraded Their MEI Pharma, Inc. (NASDAQ:MEIP) Revenue Forecasts By 25%
24 Earnings Release: Here's Why Analysts Cut Their MEI Pharma, Inc. (NASDAQ:MEIP) Price Target To US$9.50
25 A Look At MEI Pharma's (NASDAQ:MEIP) CEO Remuneration
26 MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?
27 MEIP SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies MEI Pharma, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
28 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in MEI Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline – MEIP
29 MEIP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MEI Pharma, Inc. and Encourages Investors to Contact the Firm
30 Constellation Pharma: CPI-0610 Is Well-Differentiated In The Myelofibrosis Treatment Development Pipeline
31 Micro-cap Mei Pharma lands $100M upfront on beleaguered PI3K pathway
32 Portnoy Law: Lawsuit Filed On Behalf of MEI Pharma, Inc. Investors
33 Read This Before Selling MEI Pharma, Inc. (NASDAQ:MEIP) Shares
34 Should You Buy MEI Pharma Inc (MEIP) Stock After it Is Up 11.74% in a Week?
35 Have Insiders Been Buying MEI Pharma, Inc. (NASDAQ:MEIP) Shares This Year?
36 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MEI Pharma, Inc.
37 MEI Pharma Inc (MEIP) Up 4.09% in Premarket Trading
38 Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against MEI Pharma, Inc. (MEIP)
39 ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds MEI Pharma, Inc. Investors of the Important Deadline in Securities Class Action – MEIP
40 MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Just Trimmed Their Revenue Forecasts By 0.9%
41 What Is The Ownership Structure Like For MEI Pharma, Inc. (NASDAQ:MEIP)?
42 Pomerantz Law Firm Announces the Filing of a Class Action against MEI Pharma, Inc. and Certain Officers
43 MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b Study Evaluating ME-401 on an Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies; Data to be Featured in the American Society of Clinical Oncology 2020 Virtual Scientific Program
44 Analysts Are Upgrading MEI Pharma, Inc. (NASDAQ:MEIP) After Its Latest Results
45 What Can We Learn About MEI Pharma's (NASDAQ:MEIP) CEO Compensation?
46 MEI Pharma Set To Explode With Announcement Of Lucrative Partnership
47 DEADLINE ALERT: Bragar Eagel & Squire, PC Reminds Investors That a Class Action Lawsuit Has Been Filed Against MEI Pharma, Inc. and Encourages Investors to Contact the Firm
48 BRIEF-Helsinn Group And Mei Pharma Discontinue The Phase 3 Study With Pracinostat In Aml After Completing Interim Analysis
49 MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Are Pretty Bullish On The Stock After Recent Results
50 Bragar Eagel & Squire, PC Reminds Investors That Class Action Lawsuits Have Been Filed Against MEI Pharma, Cabot Oil & Gas, Kodak, and Genius Brands and Encourages Investors to Contact the Firm
51 Why MEI Pharma's Stock Is Trading Higher Today
52 How Many MEI Pharma, Inc. (NASDAQ:MEIP) Shares Do Institutions Own?
53 How Should Investors React To MEI Pharma, Inc.'s (NASDAQ:MEIP) CEO Pay?
54 MEIP EQUITY NOTICE: ROSEN, A NATIONAL INVESTOR LAW FIRM, Encourages MEI Pharma, Inc. Investors with Losses to Contact Firm Before Important Deadline in Securities Class Action – MEIP
55 The MEI Pharma (NASDAQ:MEIP) Share Price Has Gained 41% And Shareholders Are Hoping For More
56 Earnings Update: MEI Pharma, Inc. (NASDAQ:MEIP) Just Reported And Analysts Are Trimming Their Forecasts
57 Could Mei Pharma Inc (NAQ:MEIP) be a turtle trade?
58 Kyowa Kirin invests in MEI Pharma's blood-cancer drug
59 How MEI Pharma (MEIP) Stock Stands Out in a Strong Industry
60 MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies
61 BRIEF-Mei Pharma And Kyowa Kirin Announce Updated Clinical Data From Early-Stage Follicular Lymphoma Study
62 EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against MEI Pharma, Inc. – MEIP
63 BRIEF-Helsinn And MEI Pharma Announce Updated Clinical Data From Phase 2 Study Evaluating Pracinostat In Combination With Azacitidine
64 Will MEI Pharma Inc (MEIP) Beat the Rest of the Stocks in the Healthcare Sector?
65 We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely
66 Histone Deacetylase 2 Market To Observe Exponential Growth By 2020-2027 | UpMarketResearch – NeighborWebSJ
67 MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)
68 The end of the road beckons for pracinostat
69 COVAXX, Aurobindo sign Covid-19 vaccine development deal
70 San Diego Life Sciences Roundup: MEI Pharma, Turning Point, & More
71 Is MEIP A Good Stock To Buy Now?
72 How Will Global Histone Deacetylase (Hdac) Inhibitors Market React from 2021 Onwards? – Murphy's Hockey Law
73 MEI Pharma: Best-In-Class P13K Delta Inhibitor Makes Significant Progress In The Clinic
74 Lifshitz Law Firm, PC Announces Investigation of Cognizant Technology Solutions Corporation, Honeywell International Inc., MEI Pharma, Inc., Nikola Corporation, The Chemours Company and YayYo, Inc.
75 MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies
76 Aurobindo and COVAXX sign deal to develop Covid-19 vaccine UB-612
77 MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan
78 Covid-19 Impact on Histone Deacetylase 2 Market (2020-2026) | Potential growth, attractive valuation make it is a long-term investment | Top Players: 4SC AG, Acetylon Pharmaceuticals Inc., Chipscreen Biosciences Ltd, Curis Inc., GlaxoSmithKline Plc
79 MEI Pharma licenses ME-401 to Kyowa Hakko Kirin in Japan
80 Meridian Bioscience : Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?
81 MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
82 COVAXX CEO Works to Redefine the Idea of a Vaccine
83 MEI Pharma Announces Closing of Public Offering of Common Stock
84 MEI Pharma Announces Topline Data From Phase I Clinical Trial Of Mitochondrial Inhibitor Drug Candidate ME-344
85 Imagine Owning MEI Pharma (NASDAQ:MEIP) And Trying To Stomach The 78% Share Price Drop
86 Do Directors Own MEI Pharma, Inc. (NASDAQ:MEIP) Shares?
87 Nov 18, 2020
88 UB-612 COVID-19 Vaccine
89 After Strikeout, San Diego's MEI Pharma Looks to Rebuild Confidence
90 No strings attached: COVID-19 pandemic raises profile of non-dilutive funding for life science companies
91 Asco 2020 movers – cell therapy companies dominate the risers
92 FDA Grants Fast Track Designation to PI3K Inhibitor ME-401 for Patients with FL
93 Non-Hodgkin's Lymphoma (NHL) Therapeutics Clinical Trial Analysis Report 2020
94 Another endorsement for PI3K delta, this time in oncology
95 BRIEF-MEI Pharma Announces $75 Mln Private Placement
96 Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances
97 MEI Pharma Reports Second Quarter Fiscal Year 2017 Results
98 Presage Bio Licenses Anti-Cancer Drug to San Diego's MEI Pharma
99 Cue Biopharma Welcomes Tamar Howson to its Board of Directors
100 Novogen Announces Merger Agreement With Kai Medical And Distribution Of Mei Pharma Shares